A director at Novo Nordisk AS sold 40,000 shares at 450.528DKK and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Q1 revenue missed expectations on lower reimbursement revenue, while operating profit was a beat, as opex was below our forecast and consensus. The 2025 guidance was maintained for opex of DKK2,000m–2,500m. We believe the next potential share-price catalyst is the top-line results from the phase Ib dapiglutide trial in Q2e. We reiterate our BUY, but have cut our target price to DKK950 (1,000).
Branicks Q1 25 results: Further increase in vacancy; fundamentally not improving|Teva: Q1 2025 results up slightly. Strong momentum in innovative medicines and the new efficiency programme lend credibility to the 2027 guidance.|TPG steps away from Techem acquisition; documentation subject to special call|Banco BPM reports solid Q1 performance|
Branicks Q1 25 results: Further increase in vacancy; fundamentally not improving|Teva : résultats au T1 2025 en légère hausse. La bonne dynamique des médicaments innovants et le nouveau programme d’efficience crédibilisent la guidance 2027.|TPG steps away from Techem acquisition; documentation subject to special call|BPM publie un trimestre record et au-dessus des attentes|
Q1 LCY figures beat our forecasts, while the 2025 guidance was cut to 13–21% LCY sales growth YOY and 16–24% LCY operating profit growth YOY due to weaker GLP-1 sales. We have lowered our rebate for US Ozempic but maintain our 52% Wegovy rebate (in line with the Q1 rebate when adjusting for de-stocking). We reiterate our BUY and DKK900 target price.
CVC Capital Partners étudierait une offre d’achat sur Avolta (Sky News)|Coty : nouveau profit warning à l’issue du T3|Golden Goose prépare une émission obligataire FRN de 480 m EUR|AccorInvest : Projet d’un placement obligataire de 1.25 md EUR et mise en place d’un nouveau crédit syndiqué|BPCE délivre de solides résultats T1 2025|
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.